Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Replimune Group, Inc. (REPL)
USD9.83
-0.04 (-0.42%)
US NASDAQ Healthcare Biotechnology
Address
500 Unicorn Park Drive 1801
Woburn, MA, US
Woburn, MA, US
CEO
Sushil Patel
Website
replimune.com
IPO
2018-07-20
CIK 1737953 ISIN US76029N1063
Description
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD9.83
-0.04 (-0.42%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
8M
Beta
0.87
Float Shares
76.23M
Free Float %
92.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +85.68% | +74.15% | +238.13% | +13.59% | -13.10% | -10.60% | -9.20% | -54.24% | -76.68% | -42.68% | -42.68% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (15 ratings, all time)
Buy
Price Targets & DCF
Current price
9.83
Low
14.00
+42.4%
Consensus
14.00
+42.4%
Median
14.00
+42.4%
High
14.00
+42.4%
DCF (Unlevered)
0.33
-96.6%
DCF (Levered)
0.43
-95.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
0% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | -1 |
| Buy | 0 | -5 |
| Hold | 6 | +1 |
| Sell | 2 | 0 |
| Strong Sell | 1 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 4 |
13.75
+39.9%
|
| All Time | 15 |
27.13
+176.0%
|
Quality scores
Altman Z-Score
-3.78
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-10.1% Q1'26: +20.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +387.2% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+15.2% Q1'26: +15.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.09× Q1'26: -0.09× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Mar 2025 actual |
Mar 2026 5 Rev. Ana. 6 EPS Ana. |
Mar 2027 5 Rev. Ana. 5 EPS Ana. |
Mar 2028 5 Rev. Ana. 5 EPS Ana. |
Mar 2029 4 Rev. Ana. 4 EPS Ana. |
Mar 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
—
est: 2.01M (-100.0%)
|
4.38M
581.8K – 11.08M
+117.8% YoY
|
12.38M
1.65M – 31.33M
+182.9% YoY
|
40.18M
38.01M – 42.35M
+224.7% YoY
|
157.70M
20.97M – 399.29M
+292.5% YoY
|
193.46M
25.73M – 489.83M
+22.7% YoY
|
| EBITDA |
-253.92M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-259.85M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-247.30M
est: -261.93M (+5.6%)
|
-309.76M
-315.12M – -294.64M
-18.3% YoY
|
-153.07M
-206.38M – -99.76M
+50.6% YoY
|
-159.35M
-186.76M – -34.20M
-4.1% YoY
|
-86.96M
-111.14M – -868.3K
+45.4% YoY
|
-38.98M
-116.60M – 4.95M
+55.2% YoY
|
| SGA |
—
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-3.07
est: -2.83 (-8.6%)
|
-3.25
-3.40 – -3.17
-15.0% YoY
|
-1.84
-2.22 – -1.07
+43.5% YoY
|
-1.16
-2.01 – -0.37
+36.7% YoY
|
-0.69
-1.20 – -0.01
+40.7% YoY
|
-0.42
-1.26 – 0.05
+39.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-14 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-01 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
206
Total invested
619.20M
Insider transactions (90d)
6
Beneficial owners (>5%)
39
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Baker Bros. Advisors (GP) LLC | 5.77M | 9.99% | 5.77M | — | 5.77M | — | HC, OO | — | 2023-02-14 | ↗ |
| 2 | Baker Bros. Advisors LP | 5.77M | 9.99% | 5.77M | — | 5.77M | — | IA, PN | — | 2023-02-14 | ↗ |
| 3 | Felix J. Baker | 5.77M | 9.99% | 5.77M | — | 5.77M | — | HC, IN | — | 2023-02-14 | ↗ |
| 4 | Julian C. Baker | 5.77M | 9.99% | 5.77M | — | 5.77M | — | HC, IN | — | 2023-02-14 | ↗ |
| 5 | STATE STREET CORPORATION | 5.11M | 8.65% | — | 5.01M | — | 5.11M | HC | BOSTON, MASSACHUSETTS | 2024-01-25 | ↗ |
| 6 | Otello Stampacchia | 5.06M | 10.60% | 43.5K | 5.01M | 43.5K | 5.01M | IN | — | 2022-02-14 | ↗ |
| 7 | Anne-Mari Paster | 5.01M | 10.60% | — | 5.01M | — | 5.01M | IN | — | 2022-02-14 | ↗ |
| 8 | Omega Fund IV GP Manager, Ltd. | 5.01M | 10.60% | — | 5.01M | — | 5.01M | OO | — | 2022-02-14 | ↗ |
| 9 | Omega Fund IV GP, L.P. | 5.01M | 10.60% | — | 5.01M | — | 5.01M | PN | — | 2022-02-14 | ↗ |
| 10 | Omega Fund IV, L.P. | 5.01M | 10.60% | — | 5.01M | — | 5.01M | PN | — | 2022-02-14 | ↗ |
| 11 | Jeremy C. Green | 4.78M | 9.90% | — | 4.78M | — | — | HC, IN | United Kingdom | 2022-02-14 | ↗ |
| 12 | Redmile Group, LLC | 4.78M | 9.90% | — | 4.78M | — | — | IA, OO | Delaware | 2022-02-14 | ↗ |
| 13 | Morgan Stanley | 4.39M | 7.40% | — | 13.00 | — | — | HC, CO | — | 2024-02-09 | ↗ |
| 14 | SSGA FUNDS MANAGEMENT, INC. | 4.17M | 7.07% | — | 4.17M | — | 4.17M | IA | BOSTON, MASSACHUSETTS | 2024-01-25 | ↗ |
| 15 | X, LLC | 3.83M | 10.80% | — | 3.83M | — | 10.00 | OO | Delaware | 2019-11-25 | ↗ |
| 16 | C. Green | 3.62M | 9.90% | — | 3.62M | — | 3.62M | HC | Kingdom | 2020-02-14 | ↗ |
| 17 | Group, LLC | 3.62M | 9.90% | — | 3.62M | — | 3.62M | OO | Delaware | 2020-02-14 | ↗ |
| 18 | (1) BlackRock, Inc. | 3.01M | 5.50% | 2.93M | — | 3.01M | — | HC | Delaware | 2023-02-03 | ↗ |
| 19 | 52-0556948 | 2.63M | 5.70% | 504.6K | — | 2.63M | — | IA | Maryland | 2021-02-16 | ↗ |
| 20 | Robert Coffin | 2.54M | 6.90% | 2.54M | — | 2.54M | — | IN | United States of America | 2020-02-14 | ↗ |
| 21 | BVF Inc. | 2.31M | 6.50% | — | — | — | 2.31M | CO | — | 2020-02-14 | ↗ |
| 22 | BVF Partners L.P. | 2.31M | 6.50% | — | — | — | 2.31M | IA, PN | — | 2020-02-14 | ↗ |
| 23 | Mark N. Lampert | 2.31M | 6.50% | — | — | — | 2.31M | IN | — | 2020-02-14 | ↗ |
| 24 | ATLAS VENTURE ASSOCIATES X, L.P. | 2.16M | 4.40% | — | 2.16M | — | 10.00 | PN | Delaware | 2022-09-14 | ↗ |
| 25 | ATLAS VENTURE FUND X, L.P. | 2.16M | 4.40% | — | 2.16M | — | 10.00 | PN | Delaware | 2022-09-14 | ↗ |
| 26 | BVF GP HOLDINGS LLC | 2.03M | 5.70% | — | — | — | 2.03M | OO | — | 2020-02-14 | ↗ |
| 27 | BVF I GP LLC | 1.14M | 3.20% | — | — | — | 1.14M | OO | — | 2020-02-14 | ↗ |
| 28 | Biotechnology Value Fund, L.P. | 1.14M | 3.20% | — | — | — | 1.14M | PN | — | 2020-02-14 | ↗ |
| 29 | Associates Opportunity I, L.P. | 1.10M | 3.10% | — | 1.10M | — | 10.00 | PN | Delaware | 2019-11-25 | ↗ |
| 30 | Fund I, L.P. | 1.10M | 3.10% | — | 1.10M | — | 10.00 | PN | Delaware | 2019-11-25 | ↗ |
| 31 | Opportunity I, LLC | 1.10M | 3.10% | — | 1.10M | — | 10.00 | OO | Delaware | 2019-11-25 | ↗ |
| 32 | I, L.P. | 946.0K | 1.90% | — | 946.0K | — | 10.00 | PN | Delaware | 2022-09-14 | ↗ |
| 33 | BVF II GP LLC | 894.1K | 2.50% | — | — | — | 894.1K | OO | — | 2020-02-14 | ↗ |
| 34 | Biotechnology Value Fund II, L.P. | 894.1K | 2.50% | — | — | — | 894.1K | PN | — | 2020-02-14 | ↗ |
| 35 | Foresite Capital Fund III, L.P. (“FCF III”) | 313.9K | 0.80% | 313.9K | 5.00 | 313.9K | 7.00 | PN | United States | 2020-02-14 | ↗ |
| 36 | BVF Partners OS Ltd. | 166.5K | 1.00% | — | — | — | 166.5K | CO | — | 2020-02-14 | ↗ |
| 37 | Biotechnology Value Trading Fund OS LP | 166.5K | 1.00% | — | — | — | 166.5K | PN | — | 2020-02-14 | ↗ |
| 38 | BCIP Life Sciences Associates, LP | — | 0.00% | — | — | — | — | PN | — | 2021-02-16 | ↗ |
| 39 | Bain Capital Life Sciences Fund, L.P. | — | 0.00% | — | — | — | — | PN | — | 2021-02-16 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
206
+22 vs prev Q
New positions
47
Closed positions
29
Increased
109
Reduced
54
Put/Call ratio
0.31
Calls held
5.58M
Puts held
1.75M
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BAKER BROS. ADVISORS LP | 11.05M +— (+0.0%) | 107.36M +61.1M (+132.0%) | 11.98% -0.088 pp | 0.63% +0.294 pp | USD13.46 -27.8% | 23 qtrs — |
| 2 | PRICE T ROWE ASSOCIATES INC /MD/ | 8.26M -44.1K (-0.5%) | 80.31M +45.5M (+130.7%) | 8.96% -0.114 pp | 0.01% +0.005 pp | USD21.49 -54.8% | 23 qtrs — |
| 3 | RTW INVESTMENTS, LP | 7.14M +744.6K (+11.6%) | 69.40M +42.6M (+159.0%) | 7.75% +0.757 pp | 0.70% +0.365 pp | USD6.62 +46.8% | 7 qtrs — |
| 4 | BLACKROCK, INC. | 6.07M +293.7K (+5.1%) | 59.00M +34.8M (+143.8%) | 6.58% +0.273 pp | 0.00% +0.001 pp | USD10.77 -9.7% | 6 qtrs — |
| 5 | VANGUARD GROUP INC | 3.78M +296.8K (+8.5%) | 36.70M +22.1M (+151.8%) | 4.10% +0.294 pp | 0.00% +0.000 pp | USD17.75 -45.2% | 30 qtrs — |
| 6 | STATE STREET CORP | 3.69M +769.0K (+26.3%) | 35.90M +23.6M (+193.0%) | 4.01% +0.811 pp | 0.00% +0.001 pp | USD10.50 -7.4% | 30 qtrs — |
| 7 | FMR LLC | 2.98M +1.6M (+119.1%) | 28.98M +23.3M (+408.2%) | 3.23% +1.747 pp | 0.00% +0.001 pp | USD8.69 +11.9% | 30 qtrs — |
| 8 | FCPM III SERVICES B.V. | 2.81M -1.4M (-32.5%) | 27.30M +9.9M (+56.7%) | 3.05% -1.498 pp | 3.58% +0.096 pp | USD8.18 +18.8% | 9 qtrs — |
| 9 | D. E. SHAW & CO., INC. | 2.58M +2.2M (+538.2%) | 25.03M +23.3M (+1,380.5%) | 2.79% +2.352 pp | 0.01% +0.013 pp | USD9.71 +0.1% | 13 qtrs — |
| 10 | TORONTO DOMINION BANK | 2.23M +857.5K (+62.5%) | 21.67M +15.9M (+277.0%) | 2.42% +0.919 pp | 0.03% +0.023 pp | USD6.32 +53.8% | 2 qtrs — |
| 11 | ERSTE ASSET MANAGEMENT GMBH | 2.12M +490.0K (+30.1%) | 20.62M +13.5M (+191.5%) | 2.30% +0.519 pp | 0.17% +0.105 pp | USD5.66 +71.7% | 21 qtrs — |
| 12 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.81M +1.8M (+100.0%) | 17.57M +17.6M (+100.0%) | 1.96% +1.961 pp | 0.03% +0.027 pp | USD9.72 +0.0% | 1 qtrs NEW |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 1.75M +54.7K (+3.2%) | 17.02M +9.9M (+139.5%) | 1.90% +0.046 pp | 0.00% +0.001 pp | USD16.02 -39.3% | 30 qtrs — |
| 14 | COMMODORE CAPITAL LP | 1.43M +1.4M (+100.0%) | 13.85M +13.9M (+100.0%) | 1.55% +1.546 pp | 0.92% +0.922 pp | USD9.72 +0.0% | 1 qtrs NEW |
| 15 | ROSALIND ADVISORS, INC. | 1.41M +1.4M (+100.0%) | 13.71M +13.7M (+100.0%) | 1.53% +1.530 pp | 4.82% +4.819 pp | USD9.72 +0.0% | 5 qtrs — |
| 16 | ADAR1 CAPITAL MANAGEMENT, LLC | 1.24M +262.4K (+26.8%) | 12.07M +8.0M (+194.2%) | 1.35% +0.277 pp | 0.89% +0.501 pp | USD5.40 +80.0% | 3 qtrs — |
| 17 | ALLY BRIDGE GROUP (NY) LLC | 1.20M -2.4M (-66.7%) | 11.66M -3.4M (-22.7%) | 1.30% -2.632 pp | 12.15% +2.966 pp | USD4.19 +132.0% | 2 qtrs — |
| 18 | DIMENSIONAL FUND ADVISORS LP | 1.12M -132.1K (-10.6%) | 10.88M +5.6M (+107.5%) | 1.21% -0.153 pp | 0.00% +0.001 pp | USD14.52 -33.1% | 23 qtrs — |
| 19 | REDMILE GROUP, LLC | 1.10M +563.9K (+105.2%) | 10.69M +8.4M (+376.1%) | 1.19% +0.608 pp | 0.79% +0.569 pp | USD13.64 -28.7% | 30 qtrs — |
| 20 | JPMORGAN CHASE & CO | 925.2K +887.2K (+2,333.6%) | 8.99M +8.8M (+5,545.6%) | 1.00% +0.962 pp | 0.00% +0.001 pp | USD9.96 -2.4% | 30 qtrs — |
| 21 | MILLENNIUM MANAGEMENT LLC | 834.6K -755.2K (-47.5%) | 8.11M +1.5M (+21.8%) | 0.91% -0.832 pp | 0.00% +0.001 pp | USD6.73 +44.4% | 25 qtrs — |
| 22 | MORGAN STANLEY | 814.9K -560.6K (-40.8%) | 7.92M +2.2M (+37.4%) | 0.88% -0.619 pp | 0.00% +0.000 pp | USD8.27 +17.5% | 30 qtrs — |
| 23 | BOXER CAPITAL MANAGEMENT, LLC | 750.0K -300.0K (-28.6%) | 7.29M +2.9M (+65.7%) | 0.81% -0.334 pp | 1.60% +0.193 pp | USD11.58 -16.1% | 5 qtrs — |
| 24 | JEFFERIES FINANCIAL GROUP INC. | 714.2K +714.2K (+100.0%) | 6.94M +6.9M (+100.0%) | 0.77% +0.775 pp | 0.04% +0.036 pp | USD9.72 +0.0% | 1 qtrs NEW |
| 25 | GOLDMAN SACHS GROUP INC | 658.1K -476.7K (-42.0%) | 6.40M +1.6M (+34.5%) | 0.71% -0.526 pp | 0.00% +0.000 pp | USD9.98 -2.6% | 30 qtrs — |
| 26 | INVESCO LTD. | 613.0K +458.7K (+297.3%) | 5.96M +5.3M (+821.6%) | 0.67% +0.496 pp | 0.00% +0.001 pp | USD9.50 +2.3% | 19 qtrs — |
| 27 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 606.8K +606.8K (+100.0%) | 5.90M +5.9M (+100.0%) | 0.66% +0.658 pp | 0.00% +0.001 pp | USD9.72 +0.0% | 21 qtrs — |
| 28 | UBS GROUP AG | 604.3K -297.3K (-33.0%) | 5.87M +2.1M (+55.5%) | 0.66% -0.330 pp | 0.00% +0.000 pp | USD5.75 +69.0% | 30 qtrs — |
| 29 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 587.9K +72.5K (+14.1%) | 5.71M +3.6M (+164.6%) | 0.64% +0.075 pp | 0.00% +0.001 pp | USD17.04 -43.0% | 30 qtrs — |
| 30 | JANE STREET GROUP, LLC | 584.3K +55.0 (+0.0%) | 5.68M +3.2M (+132.0%) | 0.63% -0.005 pp | 0.00% +0.001 pp | USD5.00 +94.4% | 13 qtrs — |
| 31 | NAN FUNG TRINITY (HK) LTD | 575.5K +110.0K (+23.6%) | 5.59M +3.6M (+186.8%) | 0.62% +0.116 pp | 0.44% +0.249 pp | USD9.37 +3.7% | 3 qtrs — |
| 32 | WOODLINE PARTNERS LP | 571.0K -285.0K (-33.3%) | 5.55M +2.0M (+54.7%) | 0.62% -0.316 pp | 0.02% +0.005 pp | USD13.94 -30.3% | 12 qtrs — |
| 33 | NORTHERN TRUST CORP | 539.6K -74.6K (-12.1%) | 5.24M +2.7M (+103.8%) | 0.59% -0.086 pp | 0.00% +0.000 pp | USD17.89 -45.7% | 30 qtrs — |
| 34 | BNP PARIBAS ARBITRAGE, SNC | 460.7K +446.9K (+3,247.7%) | 4.48M +4.4M (+7,665.9%) | 0.50% +0.485 pp | 0.00% +0.002 pp | USD9.64 +0.8% | 28 qtrs — |
| 35 | TWO SIGMA INVESTMENTS, LP | 444.1K +286.6K (+182.0%) | 4.32M +3.7M (+554.1%) | 0.48% +0.310 pp | 0.01% +0.005 pp | USD7.98 +21.8% | 25 qtrs — |
| 36 | RENAISSANCE TECHNOLOGIES LLC | 405.1K +405.1K (+100.0%) | 3.94M +3.9M (+100.0%) | 0.44% +0.439 pp | 0.01% +0.006 pp | USD9.72 +0.0% | 17 qtrs — |
| 37 | QUINN OPPORTUNITY PARTNERS LLC | 392.9K -257.8K (-39.6%) | 3.82M +1.1M (+40.1%) | 0.43% -0.285 pp | 0.16% -0.032 pp | USD4.19 +132.0% | 2 qtrs — |
| 38 | JUMP FINANCIAL, LLC | 296.8K +53.1K (+21.8%) | 2.89M +1.9M (+182.5%) | 0.32% +0.056 pp | 0.04% +0.023 pp | USD5.18 +87.6% | 2 qtrs — |
| 39 | BARCLAYS PLC | 292.2K +133.7K (+84.4%) | 2.84M +1.1M (+63.5%) | 0.32% +0.144 pp | 0.00% +0.000 pp | USD10.01 -2.9% | 30 qtrs — |
| 40 | TD ASSET MANAGEMENT INC | 266.5K -17.6K (-6.2%) | 2.59M +1.4M (+117.6%) | 0.29% -0.021 pp | 0.00% +0.001 pp | USD19.80 -50.9% | 23 qtrs — |
| 41 | CITADEL ADVISORS LLC | 250.2K -4.8K (-1.9%) | 2.43M +1.4M (+127.6%) | 0.27% -0.007 pp | 0.00% +0.000 pp | USD7.65 +27.1% | 16 qtrs — |
| 42 | OMEGA FUND MANAGEMENT, LLC | 248.7K +— (+0.0%) | 2.42M +1.4M (+132.0%) | 0.27% -0.002 pp | 0.84% +0.375 pp | USD15.56 -37.5% | 30 qtrs — |
| 43 | DIADEMA PARTNERS LP | 231.0K +231.0K (+100.0%) | 2.25M +2.2M (+100.0%) | 0.25% +0.251 pp | 0.39% +0.387 pp | USD9.72 +0.0% | 5 qtrs — |
| 44 | CAPTION MANAGEMENT, LLC | 228.6K +58.6K (+34.5%) | 2.22M +1.5M (+211.9%) | 0.25% +0.062 pp | 0.02% +0.010 pp | USD5.61 +73.3% | 2 qtrs — |
| 45 | BANK OF AMERICA CORP /DE/ | 215.3K +106.0K (+97.0%) | 2.09M +1.6M (+357.1%) | 0.23% +0.114 pp | 0.00% +0.000 pp | USD9.70 +0.2% | 30 qtrs — |
| 46 | BANK OF NEW YORK MELLON CORP | 209.2K +7.9K (+3.9%) | 2.03M +1.2M (+141.1%) | 0.23% +0.007 pp | 0.00% +0.000 pp | USD19.09 -49.1% | 30 qtrs — |
| 47 | WELLINGTON MANAGEMENT GROUP LLP | 208.7K -18.3K (-8.1%) | 2.03M +1.1M (+113.2%) | 0.23% -0.022 pp | 0.00% +0.000 pp | USD13.48 -27.9% | 19 qtrs — |
| 48 | J. GOLDMAN & CO LP | 205.0K +137.4K (+203.3%) | 1.99M +1.7M (+603.5%) | 0.22% +0.149 pp | 0.05% +0.045 pp | USD9.58 +1.5% | 3 qtrs — |
| 49 | HRT FINANCIAL LP | 183.6K +9.5K (+5.5%) | 1.78M +1.1M (+144.7%) | 0.20% +0.009 pp | 0.01% +0.003 pp | USD7.01 +38.7% | 7 qtrs — |
| 50 | DLD ASSET MANAGEMENT, LP | 182.4K -110.2K (-37.7%) | 1.77M +548.6K (+44.9%) | 0.20% -0.122 pp | 0.13% +0.067 pp | USD4.19 +132.0% | 2 qtrs — |
| 51 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 178.9K -38.7K (-17.8%) | 1.75M +843.1K (+92.5%) | 0.19% -0.044 pp | 0.00% +0.001 pp | USD14.67 -33.7% | 23 qtrs — |
| 52 | TREXQUANT INVESTMENT LP | 180.5K +180.5K (+100.0%) | 1.75M +1.8M (+100.0%) | 0.20% +0.196 pp | 0.02% +0.016 pp | USD9.72 +0.0% | 8 qtrs — |
| 53 | RESOLUTE CAPITAL ASSET PARTNERS LLC | 175.0K +175.0K (+100.0%) | 1.70M +1.7M (+100.0%) | 0.19% +0.190 pp | 0.82% +0.822 pp | USD9.72 +0.0% | 1 qtrs NEW |
| 54 | HUDSON BAY CAPITAL MANAGEMENT LP | 153.7K +153.7K (+100.0%) | 1.49M +1.5M (+100.0%) | 0.17% +0.167 pp | 0.00% +0.005 pp | USD9.72 +0.0% | 1 qtrs NEW |
| 55 | AMERICAN CENTURY COMPANIES INC | 148.1K +8.4K (+6.0%) | 1.44M +853.9K (+145.8%) | 0.16% +0.008 pp | 0.00% +0.000 pp | USD12.58 -22.7% | 13 qtrs — |
| 56 | RAFFERTY ASSET MANAGEMENT, LLC | 140.9K +32.3K (+29.8%) | 1.37M +914.6K (+201.0%) | 0.15% +0.034 pp | 0.00% +0.003 pp | USD9.26 +5.0% | 21 qtrs — |
| 57 | SUMMITTX CAPITAL, L.P. | 108.8K +108.8K (+100.0%) | 1.06M +1.1M (+100.0%) | 0.12% +0.118 pp | 0.03% +0.032 pp | USD9.72 +0.0% | 4 qtrs — |
| 58 | MARSHALL WACE, LLP | 93.6K +93.6K (+100.0%) | 909.6K +909.6K (+100.0%) | 0.10% +0.102 pp | 0.00% +0.001 pp | USD9.72 +0.0% | 5 qtrs — |
| 59 | WELLS FARGO & COMPANY/MN | 90.7K -64.7K (-41.6%) | 881.8K +230.8K (+35.5%) | 0.10% -0.071 pp | 0.00% +0.000 pp | USD11.32 -14.1% | 30 qtrs — |
| 60 | RHUMBLINE ADVISERS | 89.3K -10.0K (-10.1%) | 868.1K +452.0K (+108.6%) | 0.10% -0.012 pp | 0.00% +0.000 pp | USD17.63 -44.9% | 28 qtrs — |
| 61 | WALLEYE CAPITAL LLC | 86.2K +26.0K (+43.2%) | 837.9K +585.6K (+232.2%) | 0.09% +0.028 pp | 0.00% +0.002 pp | USD5.86 +65.9% | 2 qtrs — |
| 62 | WALLEYE TRADING LLC | 74.5K +36.2K (+94.5%) | 724.1K +563.7K (+351.2%) | 0.08% +0.039 pp | 0.00% +0.001 pp | USD6.88 +41.3% | 2 qtrs — |
| 63 | POINT72 ASSET MANAGEMENT, L.P. | 72.2K -3.6M (-98.0%) | 701.9K -14.5M (-95.4%) | 0.08% -3.888 pp | 0.00% -0.025 pp | USD5.27 +84.4% | 5 qtrs — |
| 64 | SG AMERICAS SECURITIES, LLC | 72.0K -26.8K (-27.1%) | 699.0K +285.0K (+68.8%) | 0.08% -0.030 pp | 0.00% -0.001 pp | USD4.90 +98.4% | 8 qtrs — |
| 65 | SQUAREPOINT OPS LLC | 67.3K -4.5K (-6.3%) | 653.9K +353.0K (+117.3%) | 0.07% -0.006 pp | 0.00% +0.000 pp | USD9.33 +4.2% | 6 qtrs — |
| 66 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 66.9K +66.9K (+100.0%) | 650.0K +650.0K (+100.0%) | 0.07% +0.073 pp | 0.01% +0.010 pp | USD9.72 +0.0% | 1 qtrs NEW |
| 67 | NAN FUNG GROUP HOLDINGS LTD | 63.7K +— (+0.0%) | 619.3K +352.4K (+132.0%) | 0.07% -0.001 pp | 0.55% +0.107 pp | USD14.23 -31.7% | 16 qtrs — |
| 68 | ALLIANCEBERNSTEIN L.P. | 62.1K -1.4K (-2.2%) | 604.0K +337.8K (+126.9%) | 0.07% -0.002 pp | 0.00% +0.000 pp | USD10.25 -5.2% | 27 qtrs — |
| 69 | ACT CAPITAL MANAGEMENT, LLC | 61.5K +61.5K (+100.0%) | 597.8K +597.8K (+100.0%) | 0.07% +0.067 pp | 0.48% +0.483 pp | USD9.72 +0.0% | 1 qtrs NEW |
| 70 | PERSISTENT ASSET PARTNERS LTD | 61.5K +61.5K (+100.0%) | 597.7K +597.7K (+100.0%) | 0.07% +0.067 pp | 0.27% +0.268 pp | USD9.72 +0.0% | 5 qtrs — |
| 71 | NUVEEN, LLC | 57.6K +— (+0.0%) | 560.0K +318.6K (+132.0%) | 0.06% -0.001 pp | 0.00% +0.000 pp | USD9.75 -0.3% | 4 qtrs — |
| 72 | ACADIAN ASSET MANAGEMENT LLC | 56.7K -16.9K (-23.0%) | 550.0K +244.0K (+79.7%) | 0.06% -0.019 pp | 0.00% +0.000 pp | USD4.19 +132.0% | 2 qtrs — |
| 73 | DEUTSCHE BANK AG\ | 53.9K -485.6K (-90.0%) | 524.3K -1.7M (-76.8%) | 0.06% -0.531 pp | 0.00% -0.001 pp | USD8.50 +14.4% | 30 qtrs — |
| 74 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 53.0K +— (+0.0%) | 514.8K +292.9K (+132.0%) | 0.06% 0.000 pp | 0.01% +0.005 pp | USD9.29 +4.6% | 3 qtrs — |
| 75 | PROFUND ADVISORS LLC | 52.1K +28.5K (+120.3%) | 506.8K +407.7K (+411.1%) | 0.06% +0.031 pp | 0.02% +0.012 pp | USD9.38 +3.6% | 12 qtrs — |
| 76 | NEOS INVESTMENT MANAGEMENT LLC | 52.1K +9.1K (+21.1%) | 505.9K +325.9K (+181.0%) | 0.06% +0.010 pp | 0.00% +0.002 pp | USD9.49 +2.4% | 4 qtrs — |
| 77 | TEMA ETFS LLC | 51.3K +8.3K (+19.4%) | 498.5K +318.4K (+176.9%) | 0.06% +0.009 pp | 0.04% +0.024 pp | USD9.49 +2.4% | 4 qtrs — |
| 78 | TUDOR INVESTMENT CORP ET AL | 50.0K +50.0K (+100.0%) | 486.0K +486.0K (+100.0%) | 0.05% +0.054 pp | 0.00% +0.001 pp | USD9.72 +0.0% | 1 qtrs NEW |
| 79 | B GROUP, INC. | 50.0K +— (+0.0%) | 486.0K +276.5K (+132.0%) | 0.05% 0.000 pp | 0.36% +0.205 pp | USD4.19 +132.0% | 2 qtrs — |
| 80 | RAYMOND JAMES FINANCIAL INC | 47.4K -139.6K (-74.7%) | 460.4K -323.1K (-41.2%) | 0.05% -0.153 pp | 0.00% 0.000 pp | USD4.39 +121.4% | 3 qtrs — |
| 81 | LOS ANGELES CAPITAL MANAGEMENT LLC | 44.0K +1.3K (+3.0%) | 451.5K +272.2K (+151.9%) | 0.05% +0.001 pp | 0.00% +0.001 pp | USD9.30 +4.5% | 9 qtrs — |
| 82 | CREATIVE PLANNING | 45.2K +24.0K (+113.1%) | 439.0K +350.2K (+394.4%) | 0.05% +0.026 pp | 0.00% +0.000 pp | USD9.11 +6.7% | 8 qtrs — |
| 83 | AQUATIC CAPITAL MANAGEMENT LLC | 44.6K +44.6K (+100.0%) | 433.8K +433.8K (+100.0%) | 0.05% +0.048 pp | 0.01% +0.012 pp | USD9.72 +0.0% | 1 qtrs NEW |
| 84 | STATE OF WISCONSIN INVESTMENT BOARD | 41.2K -217.8K (-84.1%) | 400.3K -684.8K (-63.1%) | 0.04% -0.238 pp | 0.00% -0.002 pp | USD6.40 +51.9% | 28 qtrs — |
| 85 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 40.4K +2.6K (+6.9%) | 393.0K +234.1K (+147.3%) | 0.04% +0.003 pp | 0.00% +0.000 pp | USD9.90 -1.8% | 7 qtrs — |
| 86 | SUVRETTA CAPITAL MANAGEMENT, LLC | 36.0K +36.0K (+100.0%) | 350.3K +350.3K (+100.0%) | 0.04% +0.039 pp | 0.01% +0.007 pp | USD9.72 +0.0% | 1 qtrs NEW |
| 87 | SCHONFELD STRATEGIC ADVISORS LLC | 35.2K +35.2K (+100.0%) | 342.3K +342.3K (+100.0%) | 0.04% +0.038 pp | 0.00% +0.002 pp | USD9.72 +0.0% | 9 qtrs — |
| 88 | ADVISOR GROUP HOLDINGS, INC. | 35.2K +9.1K (+35.0%) | 342.1K +227.2K (+197.6%) | 0.04% +0.010 pp | 0.00% +0.000 pp | USD9.41 +3.3% | 13 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 75 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco Dorsey Wright Healthcare Momentum ETF PTH | 1.83% | 3.11M | 0.72% |
| 2 | Virtus Biotech Clinical Trials ETF BBC | 0.76% | 438.5K | 0.65% |
| 3 | Horizon Kinetics Medical ETF MEDX | 0.75% | 138.3K | 0.85% |
| 4 | Invesco Dorsey Wright SmallCap Momentum ETF DWAS | 0.68% | 3.20M | 0.60% |
| 5 | Tema Oncology ETF CANC | 0.43% | 614.1K | 0.75% |
| 6 | Global X - S&P Biotech ETF CURE.AX | 0.28% | 100.8K | 0.45% |
| 7 | State Street SPDR S&P Biotech ETF XBI | 0.28% | 30.35M | 0.35% |
| 8 | iShares Micro-Cap ETF IWC | 0.20% | 2.93M | 0.60% |
| 9 | Invesco RAFI US 1500 Small-Mid ETF PRFZ | 0.07% | 1.99M | 0.34% |
| 10 | iShares Biotechnology ETF IBB | 0.06% | 6.02M | 0.44% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
2.38
Bullish
Ratio by volume
3.00
Bullish
Buys
19
Sells
8
Shares acquired
1.54M
Shares disposed
136.5K
Cash buys
—
Cash sales
7.00
Net activity
+1,402,597
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | Xynos Konstantinos | Officer | S-Sale | D | Common Stock | 14,023 | 5.08 | 71.2K | 235,662 | D | ↗ |
| 2026-05-18 | Schwendenman Andrew | Officer | S-Sale | D | Common Stock | 7,894 | 5.08 | 40.1K | 107,057 | D | ↗ |
| 2026-05-18 | Sarchi Christopher | Officer | S-Sale | D | Common Stock | 8,626 | 5.08 | 43.8K | 192,962 | D | ↗ |
| 2026-05-18 | Patel Sushil | Director / Officer | S-Sale | D | Common Stock | 37,324 | 5.08 | 189.6K | 747,492 | D | ↗ |
| 2026-05-18 | Hill Emily Luisa | Officer | S-Sale | D | Common Stock | 7,812 | 5.08 | 39.7K | 236,556 | D | ↗ |
| 2026-05-18 | Astley-Sparke Philip | Director | S-Sale | D | Common Stock | 17,657 | 5.08 | 89.7K | 1,412,414 | D | ↗ |
| 2026-04-02 | Sarchi Christopher | Officer | S-Sale | D | Common Stock | 6,500 | 8.01 | 52.1K | 151,588 | D | ↗ |
| 2026-04-01 | Xynos Konstantinos | Officer | A-Award | A | Employee Stock Option (right to buy) | 75,000 | 7.61 | 570.8K | 75,000 | D | ↗ |
| 2026-04-01 | Weinand Dieter | Director | A-Award | A | Stock Option (right to buy) | 44,500 | 7.61 | 338.6K | 44,500 | D | ↗ |
| 2026-04-01 | Schwendenman Andrew | Officer | A-Award | A | Employee Stock Option (right to buy) | 55,000 | 7.61 | 418.6K | 55,000 | D | ↗ |
| 2026-04-01 | Sarchi Christopher | Officer | A-Award | A | Employee Stock Option (right to buy) | 75,000 | 7.61 | 570.8K | 75,000 | D | ↗ |
| 2026-04-01 | SLATTERY JOSEPH P | Director | A-Award | A | Stock Option (right to buy) | 44,500 | 7.61 | 338.6K | 44,500 | D | ↗ |
| 2026-04-01 | Pucci Paolo | Director | A-Award | A | Stock Option (right to buy) | 44,500 | 7.61 | 338.6K | 44,500 | D | ↗ |
| 2026-04-01 | Peeples-Dyer Veleka | Director | A-Award | A | Stock Option (right to buy) | 44,500 | 7.61 | 338.6K | 44,500 | D | ↗ |
| 2026-04-01 | Patel Sushil | Director / Officer | A-Award | A | Common Stock | 251,240 | 0.00 | — | 784,816 | D | ↗ |
| 2026-04-01 | Oliger Christy J. | Director | A-Award | A | Stock Option (right to buy) | 44,500 | 7.61 | 338.6K | 44,500 | D | ↗ |
| 2026-04-01 | Hill Emily Luisa | Officer | A-Award | A | Employee Stock Option (right to buy) | 75,000 | 7.61 | 570.8K | 75,000 | D | ↗ |
| 2026-04-01 | Dhingra Kapil | Director | A-Award | A | Stock Option (right to buy) | 44,500 | 7.61 | 338.6K | 44,500 | D | ↗ |
| 2026-04-01 | Balachandran Madhavan | Director | A-Award | A | Stock Option (right to buy) | 44,500 | 7.61 | 338.6K | 44,500 | D | ↗ |
| 2026-04-01 | BAKER BROS. ADVISORS LP | Director / 10% Owner | A-Award | A | Non-Qualified Stock Option (right to buy)uy) | 44,500 | 7.61 | 338.6K | 44,500 | I | ↗ |
| 2026-04-01 | Astley-Sparke Philip | Director | A-Award | A | Stock Option (right to buy) | 75,000 | 7.61 | 570.8K | 75,000 | D | ↗ |
| 2026-02-18 | Astley-Sparke Philip | Director | G-Gift | D | Common Stock | 25,000 | 0.00 | — | 1,380,071 | D | ↗ |
| 2025-12-19 | Xynos Konstantinos | Officer | A-Award | A | Common Stock | 60,000 | 0.00 | — | 199,685 | D | ↗ |
| 2025-12-19 | Schwendenman Andrew | Officer | A-Award | A | Common Stock | 10,000 | 0.00 | — | 78,284 | D | ↗ |
| 2025-12-19 | Sarchi Christopher | Officer | A-Award | A | Common Stock | 35,000 | 0.00 | — | 158,088 | D | ↗ |
| 2025-12-19 | Patel Sushil | Director / Officer | A-Award | A | Common Stock | 200,000 | 0.00 | — | 533,576 | D | ↗ |
| 2025-12-19 | Hill Emily Luisa | Officer | A-Award | A | Common Stock | 60,000 | 0.00 | — | 194,368 | D | ↗ |
| 2025-12-09 | Dhingra Kapil | Director | M-Exempt | D | Stock Option (right to buy) | 3,169 | 1.75 | 5.5K | 0 | D | ↗ |
| 2025-12-02 | Patel Sushil | Director / Officer | S-Sale | D | Common Stock | 10,000 | 11.13 | 111.3K | 333,576 | D | ↗ |
| 2025-11-17 | Xynos Konstantinos | Officer | S-Sale | D | Common Stock | 7,248 | 9.10 | 66.0K | 139,685 | D | ↗ |
| 2025-11-17 | Sarchi Christopher | Officer | S-Sale | D | Common Stock | 5,208 | 9.10 | 47.4K | 123,088 | D | ↗ |
| 2025-08-15 | Hill Emily Luisa | Officer | S-Sale | D | Common Stock | 9,154 | 5.37 | 49.2K | 134,368 | D | ↗ |
| 2025-05-20 | Xynos Konstantinos | Officer | S-Sale | D | Common Stock | 7,952 | 8.06 | 64.1K | 146,933 | D | ↗ |
| 2025-05-20 | Schwendenman Andrew | Officer | S-Sale | D | Common Stock | 3,287 | 8.05 | 26.5K | 68,284 | D | ↗ |
| 2025-05-20 | Sarchi Christopher | Officer | S-Sale | D | Common Stock | 3,749 | 8.05 | 30.2K | 128,296 | D | ↗ |
| 2025-05-20 | Patel Sushil | Director / Officer | S-Sale | D | Common Stock | 25,105 | 8.06 | 202.3K | 343,576 | D | ↗ |
| 2025-05-20 | Hill Emily Luisa | Officer | S-Sale | D | Common Stock | 2,535 | 8.05 | 20.4K | 143,522 | D | ↗ |
| 2025-05-20 | Astley-Sparke Philip | Director | S-Sale | D | Common Stock | 32,279 | 8.06 | 260.2K | 1,405,071 | D | ↗ |
| 2025-04-01 | Xynos Konstantinos | Officer | A-Award | A | Employee Stock Option (right to buy) | 67,500 | 8.40 | 567.0K | 67,500 | D | ↗ |
| 2025-04-01 | Weinand Dieter | Director | A-Award | A | Stock Option (right to buy) | 32,000 | 8.40 | 268.8K | 32,000 | D | ↗ |
| 2025-04-01 | Schwendenman Andrew | Officer | A-Award | A | Employee Stock Option (right to buy) | 50,000 | 8.40 | 420.0K | 50,000 | D | ↗ |
| 2025-04-01 | Sarchi Christopher | Officer | A-Award | A | Employee Stock Option (right to buy) | 67,500 | 8.40 | 567.0K | 67,500 | D | ↗ |
| 2025-04-01 | SLATTERY JOSEPH P | Director | A-Award | A | Stock Option (right to buy) | 32,000 | 8.40 | 268.8K | 32,000 | D | ↗ |
| 2025-04-01 | Pucci Paolo | Director | A-Award | A | Stock Option (right to buy) | 32,000 | 8.40 | 268.8K | 32,000 | D | ↗ |
| 2025-04-01 | Peeples-Dyer Veleka | Director | A-Award | A | Stock Option (right to buy) | 32,000 | 8.40 | 268.8K | 32,000 | D | ↗ |
| 2025-04-01 | Patel Sushil | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 250,000 | 8.40 | 2.10M | 250,000 | D | ↗ |
| 2025-04-01 | Oliger Christy J. | Director | A-Award | A | Stock Option (right to buy) | 32,000 | 8.40 | 268.8K | 32,000 | D | ↗ |
| 2025-04-01 | Hill Emily Luisa | Officer | A-Award | A | Employee Stock Option (right to buy) | 67,500 | 8.40 | 567.0K | 67,500 | D | ↗ |
| 2025-04-01 | Dhingra Kapil | Director | A-Award | A | Stock Option (right to buy) | 32,000 | 8.40 | 268.8K | 32,000 | D | ↗ |
| 2025-04-01 | Balachandran Madhavan | Director | A-Award | A | Stock Option (right to buy) | 32,000 | 8.40 | 268.8K | 32,000 | D | ↗ |
| 2025-03-05 | GOLLER MICHAEL | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-03-05 | BAKER BROS. ADVISORS LP | Director / 10% Owner | A-Award | A | Non-Qualified Stock Option (right to buy)uy) | 64,000 | 12.29 | 786.6K | 64,000 | I | ↗ |
| 2024-12-16 | Patel Sushil | Director / Officer | S-Sale | D | Common Stock | 10,000 | 12.42 | 124.2K | 202,014 | D | ↗ |
| 2024-11-18 | Xynos Konstantinos | Officer | S-Sale | D | Common Stock | 7,246 | 10.78 | 78.1K | 109,885 | D | ↗ |
| 2024-11-18 | Sarchi Christopher | Officer | S-Sale | D | Common Stock | 5,207 | 10.78 | 56.1K | 87,045 | D | ↗ |
| 2024-09-04 | Balachandran Madhavan | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-08-30 | Astley-Sparke Philip | Director / Officer | G-Gift | D | Common Stock | 50,000 | 0.00 | — | 1,437,350 | — | ↗ |
| 2024-08-16 | Hill Emily Luisa | Officer | S-Sale | D | Common Stock | 8,938 | 10.18 | 91.0K | 101,057 | — | ↗ |
| 2024-06-07 | Xynos Konstantinos | Officer | S-Sale | D | Common Stock | 15,881 | 7.50 | 119.1K | 117,131 | — | ↗ |
| 2024-05-16 | Xynos Konstantinos | Officer | S-Sale | D | Common Stock | 6,367 | 6.47 | 41.2K | 133,012 | — | ↗ |
| 2024-05-16 | Schwendenman Andrew | Officer | S-Sale | D | Common Stock | 2,298 | 6.47 | 14.9K | 38,238 | — | ↗ |
| 2024-05-16 | Sarchi Christopher | Officer | S-Sale | D | Common Stock | 2,218 | 6.47 | 14.4K | 92,252 | — | ↗ |
| 2024-05-16 | Patel Sushil | Director / Officer | S-Sale | D | Common Stock | 20,194 | 6.47 | 130.7K | 212,014 | — | ↗ |
| 2024-05-16 | Love Colin | Officer | S-Sale | D | Common Stock | 17,615 | 6.47 | 114.0K | 777,345 | — | ↗ |
| 2024-05-16 | Coffin Robert | Director | S-Sale | D | Common Stock | 11,464 | 6.47 | 74.2K | 1,821,872 | — | ↗ |
| 2024-05-16 | Astley-Sparke Philip | Director / Officer | S-Sale | D | Common Stock | 37,928 | 6.47 | 245.4K | 1,487,350 | — | ↗ |
| 2024-04-01 | Xynos Konstantinos | Officer | A-Award | A | Common Stock | 26,665 | 0.00 | — | 139,379 | — | ↗ |
| 2024-04-01 | Weinand Dieter | Director | A-Award | A | Stock Option (right to buy) | 32,000 | 7.73 | 247.4K | 32,000 | — | ↗ |
| 2024-04-01 | Schwendenman Andrew | Officer | A-Award | A | Employee Stock Option (right to buy) | 53,325 | 7.73 | 412.2K | 53,325 | — | ↗ |
| 2024-04-01 | Sarchi Christopher | Officer | A-Award | A | Common Stock | 22,225 | 0.00 | — | 94,470 | — | ↗ |
| 2024-04-01 | SLATTERY JOSEPH P | Director | A-Award | A | Stock Option (right to buy) | 32,000 | 7.73 | 247.4K | 32,000 | — | ↗ |
| 2024-04-01 | Pucci Paolo | Director | A-Award | A | Stock Option (right to buy) | 32,000 | 7.73 | 247.4K | 32,000 | — | ↗ |
| 2024-04-01 | Peeples-Dyer Veleka | Director | A-Award | A | Stock Option (right to buy) | 32,000 | 7.73 | 247.4K | 32,000 | — | ↗ |
| 2024-04-01 | Patel Sushil | Director / Officer | A-Award | A | Common Stock | 83,335 | 0.00 | — | 232,208 | — | ↗ |
| 2024-04-01 | Oliger Christy J. | Director | A-Award | A | Stock Option (right to buy) | 32,000 | 7.73 | 247.4K | 32,000 | — | ↗ |
| 2024-04-01 | Levitsky Hyam | Director | A-Award | A | Stock Option (right to buy) | 32,000 | 7.73 | 247.4K | 32,000 | — | ↗ |
| 2024-04-01 | Hill Emily Luisa | Officer | A-Award | A | Employee Stock Option (right to buy) | 80,000 | 7.73 | 618.4K | 80,000 | — | ↗ |
| 2024-04-01 | Dhingra Kapil | Director | A-Award | A | Stock Option (right to buy) | 32,000 | 7.73 | 247.4K | 32,000 | — | ↗ |
| 2023-11-16 | Xynos Konstantinos | Officer | S-Sale | D | Common Stock | 7,313 | 10.92 | 79.9K | 112,714 | — | ↗ |
| 2023-11-16 | Sarchi Christopher | Officer | S-Sale | D | Common Stock | 5,255 | 10.92 | 57.4K | 72,245 | — | ↗ |
| 2023-09-18 | Hill Emily Luisa | Officer | A-Award | A | Employee Stock Option (right to buy) | 125,000 | 18.00 | 2.25M | 125,000 | — | ↗ |
| 2023-09-12 | Esposito Pamela | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 300 | 3.30 | 990.00 | 86,033 | — | ↗ |
| 2023-09-11 | Esposito Pamela | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 5,358 | 3.30 | 17.7K | 86,333 | — | ↗ |
| 2023-08-22 | Esposito Pamela | Officer | M-Exempt | A | Common Stock | 5,000 | 15.50 | 77.5K | 282,036 | — | ↗ |
| 2023-08-11 | Esposito Pamela | Officer | M-Exempt | A | Common Stock | 1,400 | 3.30 | 4.6K | 264,836 | — | ↗ |
| 2023-07-17 | Sarchi Christopher | Officer | — | D | Common Stock | 0 | 0.00 | — | 55,000 | — | ↗ |
| 2023-07-10 | Esposito Pamela | Officer | S-Sale | D | Common Stock | 2,077 | 21.12 | 43.9K | 263,436 | — | ↗ |
| 2023-06-13 | Patel Sushil | Officer | S-Sale | D | Common Stock | 5,145 | 24.11 | 124.0K | 149,426 | — | ↗ |
| 2023-06-13 | Lewis Tanya | Officer | S-Sale | D | Common Stock | 12,043 | 24.10 | 290.2K | 136,110 | — | ↗ |
| 2023-06-01 | Peeples-Dyer Veleka | Director | A-Award | A | Employee Stock Option (right to buy) | 50,400 | 18.48 | 931.4K | 50,400 | — | ↗ |
| 2023-05-18 | Schwendenman Andrew | Officer | — | D | Common Stock | 0 | 0.00 | — | 22,761 | — | ↗ |
| 2023-05-16 | Xynos Konstantinos | Officer | S-Sale | D | Common Stock | 771 | 18.05 | 13.9K | 120,027 | — | ↗ |
| 2023-05-16 | Patel Sushil | Officer | S-Sale | D | Common Stock | 15,575 | 18.05 | 281.1K | 154,571 | — | ↗ |
| 2023-05-16 | Love Colin | Officer | S-Sale | D | Common Stock | 10,775 | 18.05 | 194.5K | 794,960 | — | ↗ |
| 2023-05-16 | Lewis Tanya | Officer | S-Sale | D | Common Stock | 12,207 | 18.05 | 220.3K | 148,153 | — | ↗ |
| 2023-05-16 | Franchi Jean M. | Officer | S-Sale | D | Common Stock | 11,351 | 18.05 | 204.9K | 128,748 | — | ↗ |
| 2023-05-16 | Esposito Pamela | Officer | S-Sale | D | Common Stock | 5,966 | 18.05 | 107.7K | 263,436 | — | ↗ |
| 2023-05-16 | Coffin Robert | Director / Officer | S-Sale | D | Common Stock | 7,861 | 18.05 | 141.9K | 1,833,336 | — | ↗ |
| 2023-05-16 | Astley-Sparke Philip | Director / Officer | S-Sale | D | Common Stock | 17,902 | 18.05 | 323.1K | 1,525,278 | — | ↗ |
| 2023-04-01 | Xynos Konstantinos | Officer | A-Award | A | Employee Stock Option (right to buy) | 75,000 | 17.66 | 1.32M | 75,000 | — | ↗ |
| 2023-04-01 | Weinand Dieter | Director | A-Award | A | Stock Option (right to buy) | 37,800 | 17.66 | 667.5K | 37,800 | — | ↗ |
| 2023-04-01 | Slootweg Hugo Alexander | Director | A-Award | A | Stock Option (right to buy) | 25,200 | 17.66 | 445.0K | 25,200 | — | ↗ |
| 2023-04-01 | SLATTERY JOSEPH P | Director | A-Award | A | Stock Option (right to buy) | 25,200 | 17.66 | 445.0K | 25,200 | — | ↗ |
| 2023-04-01 | Pucci Paolo | Director | A-Award | A | Stock Option (right to buy) | 25,200 | 17.66 | 445.0K | 25,200 | — | ↗ |
| 2023-04-01 | Patel Sushil | Officer | A-Award | A | Employee Stock Option (right to buy) | 60,000 | 17.66 | 1.06M | 60,000 | — | ↗ |
| 2023-04-01 | Oliger Christy J. | Director | A-Award | A | Stock Option (right to buy) | 25,200 | 17.66 | 445.0K | 25,200 | — | ↗ |
| 2023-04-01 | Love Colin | Officer | A-Award | A | Employee Stock Option (right to buy) | 60,000 | 17.66 | 1.06M | 60,000 | — | ↗ |
| 2023-04-01 | Lewis Tanya | Officer | A-Award | A | Common Stock | 40,000 | 0.00 | — | 160,360 | — | ↗ |
| 2023-04-01 | Levitsky Hyam | Director | A-Award | A | Stock Option (right to buy) | 25,200 | 17.66 | 445.0K | 25,200 | — | ↗ |
| 2023-04-01 | Franchi Jean M. | Officer | A-Award | A | Common Stock | 45,000 | 0.00 | — | 140,099 | — | ↗ |
| 2023-04-01 | Esposito Pamela | Officer | A-Award | A | Common Stock | 40,000 | 0.00 | — | 269,402 | — | ↗ |
| 2023-04-01 | Dhingra Kapil | Director | A-Award | A | Stock Option (right to buy) | 25,200 | 17.66 | 445.0K | 25,200 | — | ↗ |
| 2023-04-01 | Coffin Robert | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 67,500 | 17.66 | 1.19M | 67,500 | — | ↗ |
| 2023-04-01 | Astley-Sparke Philip | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 213,150 | 17.66 | 3.76M | 213,150 | — | ↗ |
| 2022-12-09 | Esposito Pamela | Officer | M-Exempt | A | Common Stock | 15,000 | 1.01 | 15.2K | 244,402 | — | ↗ |
| 2022-12-01 | Xynos Konstantinos | Officer | — | D | Employee Stock Option (right to buy) | 10,500 | 18.26 | 191.7K | — | — | ↗ |
| 2022-05-16 | Patel Sushil | Officer | S-Sale | D | Common Stock | 10,687 | 14.59 | 155.9K | 130,146 | — | ↗ |
| 2022-05-16 | Love Colin | Officer | S-Sale | D | Common Stock | 6,324 | 14.59 | 92.3K | 765,735 | — | ↗ |
| 2022-05-16 | Lewis Tanya | Officer | S-Sale | D | Common Stock | 5,473 | 14.59 | 79.9K | 120,360 | — | ↗ |
| 2022-05-16 | Franchi Jean M. | Officer | S-Sale | D | Common Stock | 3,436 | 14.59 | 50.1K | 95,099 | — | ↗ |
| 2022-05-16 | Esposito Pamela | Officer | S-Sale | D | Common Stock | 3,507 | 14.59 | 51.2K | 229,402 | — | ↗ |
| 2022-05-16 | Coffin Robert | Officer | S-Sale | D | Common Stock | 5,737 | 14.59 | 83.7K | 1,796,197 | — | ↗ |
| 2022-05-16 | Astley-Sparke Philip | Officer | S-Sale | D | Common Stock | 9,632 | 14.59 | 140.5K | 1,401,080 | — | ↗ |
| 2022-04-01 | Weinand Dieter | Director | A-Award | A | Stock Option (right to buy) | 24,750 | 0.00 | — | 24,750 | — | ↗ |
| 2022-04-01 | Slootweg Hugo Alexander | Director | A-Award | A | Stock Option (right to buy) | 16,500 | 0.00 | — | 16,500 | — | ↗ |
| 2022-04-01 | SLATTERY JOSEPH P | Director | A-Award | A | Stock Option (right to buy) | 16,500 | 0.00 | — | 16,500 | — | ↗ |
| 2022-04-01 | Rhodes Jason P | Director | A-Award | A | Stock Option (right to buy) | 16,500 | 18.26 | 301.3K | 16,500 | — | ↗ |
| 2022-04-01 | Pucci Paolo | Director | A-Award | A | Stock Option (right to buy) | 16,500 | 0.00 | — | 16,500 | — | ↗ |
| 2022-04-01 | Patel Sushil | Officer | A-Award | A | Common Stock | 52,500 | 0.00 | — | 140,833 | — | ↗ |
| 2022-04-01 | Oliger Christy J. | Director | A-Award | A | Stock Option (right to buy) | 16,500 | 0.00 | — | 16,500 | — | ↗ |
| 2022-04-01 | Love Colin | Officer | A-Award | A | Employee Stock Option (right to buy) | 39,375 | 18.26 | 719.0K | 39,375 | — | ↗ |
| 2022-04-01 | Lewis Tanya | Officer | A-Award | A | Employee Stock Option (right to buy) | 78,750 | 0.00 | — | 78,750 | — | ↗ |
| 2022-04-01 | Levitsky Hyam | Director | A-Award | A | Stock Option (right to buy) | 16,500 | 0.00 | — | 16,500 | — | ↗ |
| 2022-04-01 | Franchi Jean M. | Officer | A-Award | A | Employee Stock Option (right to buy) | 78,750 | 0.00 | — | 78,750 | — | ↗ |
| 2022-04-01 | Esposito Pamela | Officer | A-Award | A | Employee Stock Option (right to buy) | 34,125 | 18.26 | 623.1K | 34,125 | — | ↗ |
| 2022-04-01 | Dhingra Kapil | Director | A-Award | A | Stock Option (right to buy) | 16,500 | 0.00 | — | 16,500 | — | ↗ |
| 2022-04-01 | Coffin Robert | Officer | A-Award | A | Common Stock | 26,250 | 0.00 | — | 1,801,934 | — | ↗ |
| 2022-04-01 | Astley-Sparke Philip | Officer | A-Award | A | Employee Stock Option (right to buy) | 105,000 | 0.00 | — | 105,000 | — | ↗ |
| 2022-03-14 | Stampacchia Otello | Director | S-Sale | D | Common Stock | 38,762 | 15.55 | 602.7K | 4,673,380 | — | ↗ |
| 2021-12-01 | Oliger Christy J. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-11-22 | Omega Fund IV, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 10,162 | 34.70 | 352.6K | 4,763,380 | — | ↗ |
| 2021-11-19 | Omega Fund IV, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 417 | 34.80 | 14.5K | 4,773,542 | — | ↗ |
| 2021-11-18 | Omega Fund IV, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 2,441 | 33.50 | 81.8K | 4,808,804 | D | ↗ |
| 2021-11-16 | Omega Fund IV, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 153 | 33.50 | 5.1K | 4,811,245 | D | ↗ |
| 2021-11-15 | Omega Fund IV, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 782 | 33.66 | 26.3K | 4,811,398 | — | ↗ |
| 2021-11-12 | Omega Fund IV, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 23,235 | 33.66 | 782.1K | 4,812,180 | — | ↗ |
| 2021-11-11 | Omega Fund IV, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 18,279 | 33.61 | 614.4K | 4,835,415 | — | ↗ |
| 2021-11-10 | Omega Fund IV, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 11 | 33.50 | 368.50 | 4,853,694 | — | ↗ |
| 2021-11-09 | Omega Fund IV, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 7,537 | 33.73 | 254.2K | 4,853,705 | — | ↗ |
| 2021-11-08 | Omega Fund IV, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 3,817 | 33.53 | 128.0K | 4,861,242 | — | ↗ |
| 2021-11-05 | Omega Fund IV, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 5,790 | 33.50 | 194.0K | 4,865,059 | — | ↗ |
| 2021-11-04 | Omega Fund IV, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 25,225 | 33.58 | 847.1K | 4,870,849 | — | ↗ |
| 2021-10-18 | Love Colin | Officer | S-Sale | D | Common Stock | 12,711 | 29.58 | 376.0K | 745,809 | — | ↗ |
| 2021-10-15 | Love Colin | Officer | S-Sale | D | Common Stock | 2,200 | 31.16 | 68.6K | 773,609 | — | ↗ |
| 2021-09-23 | Omega Fund IV, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 12,171 | 33.58 | 408.7K | 4,896,074 | — | ↗ |
| 2021-09-17 | Omega Fund IV, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 78,998 | 32.88 | 2.60M | 4,923,710 | — | ↗ |
| 2021-09-16 | Omega Fund IV, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 5,537 | 32.55 | 180.2K | 5,002,708 | — | ↗ |
| 2021-09-15 | Love Colin | Officer | S-Sale | D | Common Stock | 30,000 | 31.23 | 936.9K | 775,809 | — | ↗ |
| 2021-08-16 | Love Colin | Officer | S-Sale | D | Common Stock | 27,300 | 30.00 | 819.0K | 808,509 | — | ↗ |
| 2021-08-05 | Esposito Pamela | Officer | S-Sale | D | Common Stock | 25,800 | 35.09 | 905.3K | 210,159 | — | ↗ |
| 2021-08-04 | Esposito Pamela | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 4,200 | 15.50 | 65.1K | 71,550 | — | ↗ |
| 2021-07-21 | Esposito Pamela | Officer | M-Exempt | A | Common Stock | 12,538 | 1.01 | 12.7K | 222,697 | — | ↗ |
| 2021-07-20 | Esposito Pamela | Officer | M-Exempt | A | Common Stock | 4,862 | 1.01 | 4.9K | 215,021 | — | ↗ |
| 2021-07-15 | Love Colin | Officer | S-Sale | D | Common Stock | 30,000 | 32.02 | 960.6K | 835,809 | — | ↗ |
| 2021-07-15 | Esposito Pamela | Officer | S-Sale | D | Common Stock | 4,600 | 33.37 | 153.5K | 210,159 | — | ↗ |
| 2021-07-02 | Coffin Robert | Director / Officer | S-Sale | D | Common Stock | 7,810 | 40.04 | 312.7K | 1,775,684 | — | ↗ |
| 2021-06-29 | Coffin Robert | Director / Officer | S-Sale | D | Common Stock | 22,826 | 40.05 | 914.2K | 1,783,494 | — | ↗ |
| 2021-06-28 | Coffin Robert | Director / Officer | S-Sale | D | Common Stock | 14,663 | 40.04 | 587.1K | 1,806,320 | — | ↗ |
| 2021-06-15 | Love Colin | Officer | S-Sale | D | Common Stock | 17,800 | 33.80 | 601.6K | 878,009 | — | ↗ |
| 2021-05-10 | Lewis Tanya | Officer | A-Award | A | Employee Stock Option (right to buy) | 110,000 | 33.99 | 3.74M | 110,000 | — | ↗ |
| 2021-05-03 | Patel Sushil | Officer | A-Award | A | Common Stock | 88,333 | 0.00 | — | 88,333 | — | ↗ |
| 2021-04-15 | Love Colin | Officer | S-Sale | D | Common Stock | 27,300 | 30.69 | 837.8K | 898,509 | — | ↗ |
| 2021-04-01 | Weinand Dieter | Director | A-Award | A | Stock Option (right to buy) | 24,750 | 31.58 | 781.6K | 24,750 | — | ↗ |
| 2021-04-01 | Slootweg Hugo Alexander | Director | A-Award | A | Stock Option (right to buy) | 16,500 | 31.58 | 521.1K | 16,500 | — | ↗ |
| 2021-04-01 | SLATTERY JOSEPH P | Director | A-Award | A | Stock Option (right to buy) | 16,500 | 31.58 | 521.1K | 16,500 | — | ↗ |
| 2021-04-01 | Rhodes Jason P | Director | A-Award | A | Stock Option (right to buy) | 16,500 | 31.58 | 521.1K | 16,500 | — | ↗ |
| 2021-04-01 | Pucci Paolo | Director | A-Award | A | Stock Option (right to buy) | 16,500 | 31.58 | 521.1K | 16,500 | — | ↗ |
| 2021-04-01 | Pirzkall Andrea | Officer | A-Award | A | Common Stock | 20,500 | 0.00 | — | 21,500 | — | ↗ |
| 2021-04-01 | Omega Fund IV, L.P. | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 16,500 | 31.58 | 521.1K | 16,500 | — | ↗ |
| 2021-04-01 | Love Colin | Officer | A-Award | A | Common Stock | 39,285 | 0.00 | — | 925,809 | — | ↗ |
| 2021-04-01 | Lewis Tanya | Director | A-Award | A | Stock Option (right to buy) | 16,500 | 31.58 | 521.1K | 16,500 | — | ↗ |
| 2021-04-01 | Levitsky Hyam | Director | A-Award | A | Stock Option (right to buy) | 16,500 | 31.58 | 521.1K | 16,500 | — | ↗ |
| 2021-04-01 | Franchi Jean M. | Officer | A-Award | A | Common Stock | 46,035 | 0.00 | — | 46,035 | — | ↗ |
| 2021-04-01 | Esposito Pamela | Officer | A-Award | A | Employee Stock Option (right to buy) | 51,250 | 31.58 | 1.62M | 51,250 | — | ↗ |
| 2021-04-01 | Dhingra Kapil | Director | A-Award | A | Stock Option (right to buy) | 16,500 | 31.58 | 521.1K | 16,500 | — | ↗ |
| 2021-04-01 | Coffin Robert | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 115,300 | 31.58 | 3.64M | 115,300 | — | ↗ |
| 2021-04-01 | Astley-Sparke Philip | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 128,125 | 31.58 | 4.05M | 128,125 | — | ↗ |
| 2021-03-15 | Love Colin | Officer | S-Sale | D | Common Stock | 18,518 | 33.22 | 615.2K | 886,624 | — | ↗ |
| 2021-02-16 | Love Colin | Officer | S-Sale | D | Common Stock | 18,620 | 36.61 | 681.7K | 927,904 | — | ↗ |
| 2021-02-08 | Omega Fund IV, L.P. | 10% Owner | S-Sale | D | Common Stock | 5,249 | 45.00 | 236.2K | 5,141,321 | — | ↗ |
| 2021-01-26 | Rhodes Jason P | Director | S-Sale | D | Common Stock | 5,558 | 46.14 | 256.4K | 946,000 | — | ↗ |
| 2021-01-26 | Omega Fund IV, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 3,393 | 46.04 | 156.2K | 5,283,682 | — | ↗ |
| 2021-01-22 | Omega Fund IV, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 3,269 | 45.03 | 147.2K | 5,314,032 | — | ↗ |
| 2021-01-22 | Coffin Robert | Director / Officer | S-Sale | D | Common Stock | 29,803 | 43.99 | 1.31M | 1,744,118 | — | ↗ |
| 2021-01-19 | Love Colin | Officer | S-Sale | D | Common Stock | 7,157 | 42.38 | 303.3K | 946,524 | — | ↗ |
| 2021-01-19 | Esposito Pamela | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 5,727 | 1.01 | 5.8K | 73,203 | D | ↗ |
| 2021-01-19 | Astley-Sparke Philip | Director / Officer | S-Sale | D | Common Stock | 7,632 | 42.40 | 323.6K | 1,255,297 | — | ↗ |
| 2021-01-15 | Omega Fund IV, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 1,916 | 45.19 | 86.6K | 5,325,391 | — | ↗ |
| 2021-01-15 | Love Colin | Officer | S-Sale | D | Common Stock | 12,396 | 43.07 | 533.9K | 954,381 | — | ↗ |
| 2021-01-15 | Esposito Pamela | Officer | S-Sale | D | Common Stock | 29,273 | 43.58 | 1.28M | 175,994 | D | ↗ |
Executive team
Top executives
Shares Outstanding
82.57M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Sushil Patel Chief Executive Officer | 600.0K | — | 1.29M | 1.35M | 450.0K | 13.4K | 3.70M | 71.24% | ↗ |
| 2 | 2025 | Konstantinos Xynos Chief Medical Officer | 516.5K | — | 412.2K | 430.7K | 253.1K | 12.4K | 1.62M | 51.88% | ↗ |
| 3 | 2025 | Emily Hill Chief Financial Officer | 516.5K | — | 412.2K | 430.7K | 235.5K | — | 1.59M | 52.85% | ↗ |
| 4 | 2024 | Philip Astley-Sparke Chief Executive Officer | 649.0K | — | 2.51M | 2.55M | 311.5K | — | 6.02M | 84.04% | ↗ |
| 5 | 2024 | Emily Hill Chief Financial Officer | 266.5K | — | 1.50M | 1.52M | 96.0K | — | 3.38M | 89.29% | ↗ |
| 6 | 2024 | Konstantinos Xynos Chief Medical Officer | 499.2K | — | 883.0K | 896.7K | 157.2K | 12.2K | 2.45M | 72.69% | ↗ |
| 7 | 2024 | Sushil Patel Chief Executive Officer | 464.9K | — | 706.4K | 717.3K | 162.7K | 11.8K | 2.06M | 69.01% | ↗ |
| 8 | 2023 | Philip Astley-Sparke Chief Executive Officer | 624.0K | — | 1.28M | 1.30M | 449.3K | — | 3.65M | 70.57% | ↗ |
| 9 | 2023 | Jean Franchi Chief Financial Officer and Treasurer | 464.5K | — | 958.7K | 971.3K | 213.7K | — | 2.61M | 74.00% | ↗ |
| 10 | 2023 | Sushil Patel Chief Strategy Officer | 447.0K | — | 958.7K | 971.3K | 205.6K | 12.4K | 2.60M | 74.37% | ↗ |
| 11 | 2022 | Sushil Patel Chief Commercial Officer | 394.2K | — | 3.25M | 3.15M | 152.7K | 9.5K | 6.95M | 92.00% | ↗ |
| 12 | 2022 | Sushil Patel Chief Strategy Officer | 394.2K | — | 3.25M | 3.15M | 152.7K | 9.5K | 6.95M | 92.00% | ↗ |
| 13 | 2022 | Philip Astley-Sparke Chief Executive Officer | 600.0K | — | 2.70M | 2.79M | 280.5K | — | 6.37M | 86.17% | ↗ |
| 14 | 2022 | Robert Coffin, Ph.D. President and Chief Research & Development Officer | 551.5K | — | 2.43M | 2.51M | 234.4K | — | 5.72M | 86.27% | ↗ |
| 15 | 2021 | Andrea Pirzkall Chief Medical Officer | 261.4K | — | — | 4.38M | 85.3K | — | 4.73M | 92.67% | ↗ |
| 16 | 2021 | Philip Astley-Sparke Chief Executive Officer | 533.0K | — | — | 1.70M | 226.5K | — | 2.46M | 69.09% | ↗ |
| 17 | 2021 | Robert Coffin, Ph.D. President and Chief Research & Development Officer | 533.0K | — | — | 1.70M | 226.5K | — | 2.46M | 69.09% | ↗ |
| 18 | 2020 | Robert Coffin, Ph.D. President and Chief Research & Development Officer | 517.5K | — | — | 2.21M | 208.3K | — | 2.93M | 75.26% | ↗ |
| 19 | 2020 | Philip Astley-Sparke Chief Executive Officer | 437.8K | — | — | 1.54M | 176.2K | — | 2.16M | 71.51% | ↗ |
| 20 | 2020 | Jean Franchi Chief Financial Officer | 132.4K | — | — | 1.63M | 42.6K | — | 1.80M | 90.29% | ↗ |
| 21 | 2020 | Howard Kaufman, M.D. Former Chief Medical Officer | 315.0K | — | — | 810.6K | — | 149.0K | 1.27M | 63.60% | ↗ |
| 22 | 2020 | Pamela Esposito, Ph.D. Chief Business Officer | 362.5K | — | — | 762.8K | 102.1K | — | 1.23M | 62.15% | ↗ |
| 23 | 2019 | Robert Coffin, Ph.D. President, Chief Executive Officer and Director | 478.0K | — | — | 1.55M | 239.0K | — | 2.27M | 68.36% | ↗ |
| 24 | 2019 | Robert Coffin, Ph.D. President and Chief Research & Development Officer | 478.0K | — | — | 1.55M | 239.0K | — | 2.27M | 68.36% | ↗ |
| 25 | 2019 | Howard Kaufman, M.D. Chief Scientific Officer | 406.0K | — | — | 1.33M | 142.1K | — | 1.88M | 70.78% | ↗ |
| 26 | 2019 | Howard Kaufman, M.D. Former Chief Medical Officer | 406.0K | — | — | 1.33M | 142.1K | — | 1.88M | 70.78% | ↗ |
| 27 | 2019 | Philip Astley-Sparke Executive Chairman, Treasurer, Secretary and Director | 382.4K | — | — | 1.24M | 191.2K | — | 1.81M | 68.36% | ↗ |
| 28 | 2019 | Philip Astley-Sparke Chief Executive Officer | 382.4K | — | — | 1.24M | 191.2K | — | 1.81M | 68.36% | ↗ |
| 29 | 2019 | Colin Love, Ph.D. Chief Operating Officer | 310.6K | — | — | 885.0K | 108.7K | — | 1.30M | 67.85% | ↗ |
| 30 | 2018 | Robert Coffin, Ph.D. President, Chief Executive Officer and Director | 389.5K | — | — | 592.0K | 146.8K | — | 1.13M | 52.47% | ↗ |
| 31 | 2018 | Colin Love, Ph.D. Chief Operating Officer | 311.8K | — | — | 277.5K | 101.8K | — | 691.1K | 40.15% | ↗ |
| 32 | 2018 | Philip Astley-Sparke Executive Chairman, Treasurer, Secretary and Director | 254.7K | — | — | 166.5K | 83.8K | — | 505.0K | 32.97% | ↗ |
CEO compensation breakdown
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sushil Patel | Chief Executive Officer & Director | 1M | male |
| Philip Astley-Sparke | Executive Chairman | 960.5K | male |
| Konstantinos Xynos | Chief Medical Officer | 781.9K | — |
| Emily Luisa Hill | Chief Financial Officer | 752.0K | female |
| Christopher Sarchi | Chief Commercial Officer | 594.6K | male |
| Nina Aragam | Senior Vice President of Portfolio Strategy & Program Management | — | female |
| Paul Bullock | Chief Manufacturing Officer & Framingham Site Head | — | male |
| Carolyn Trott | Senior Vice President of Quality Assurance | — | female |
| Shawn Glidden | Senior Vice President & General Counsel | — | male |
| Camilo Garcia | Chief Human Resource Officer | — | male |
| Andrew Schwendenman | Chief Accounting Officer & Treasurer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for REPL
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
